Evidence map›Paper›PMID 31182043›Full record

ArticleBMC infectious diseases2019

Serologic testing of randomly selected children after hepatitis B vaccination: a cross-sectional population-based study in Lao People's Democratic Republic.

Masataro Norizuki, Tomomi Kitamura, Kenichi Komada, Masaya Sugiyama, Masashi Mizokami, Anonh Xeuatvongsa, Vilasak Som-Oulay, Phengta Vongphrachanh, Munehito Machida, Koji Wada and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Immune response to GeneVac-BIJID regions · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Masataro NorizukiBureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan. m-norizuki@it.ncgm.go.jp.ORCID http://orcid.org/0000-0002-1809-9796
Tomomi KitamuraBureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan.
Kenichi KomadaBureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan.
Masaya SugiyamaThe Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan.
Masashi MizokamiThe Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan.
Anonh XeuatvongsaNational Immunization Program, Ministry of Health, Lao PDR, Simeuang Road, Vientiane, Lao PDR.
Vilasak Som-OulayNational Center for Laboratory and Epidemiology, Ministry of Health, Lao PDR, Simeuang Road, Vientiane, Lao PDR.
Phengta VongphrachanhNational Center for Laboratory and Epidemiology, Ministry of Health, Lao PDR, Simeuang Road, Vientiane, Lao PDR.
Munehito MachidaBureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan.
Koji WadaBureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan.
Koji IshiiDepartment of Virology II, National Institute of Infectious Diseases, Musashi-murayama, Tokyo, Japan.
Tomoko KiyoharaDepartment of Virology II, National Institute of Infectious Diseases, Musashi-murayama, Tokyo, Japan.
Takaji WakitaDepartment of Virology II, National Institute of Infectious Diseases, Musashi-murayama, Tokyo, Japan.
Masahiko HachiyaBureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan.
National Center for Global Health and Medicine · JPNational Institute of Infectious Diseases · JPMinistry of Health · GRKanazawa University · JP

Funding

National Center for Global Health and Medicine 22-7National Center for Global Health and Medicine 27-4National Center for Global Health and Medicine 28-1National Center for Global Health and Medicine 30-6
6 · The paper itself

Abstract

backgroundPopulation immunity against hepatitis B virus (HBV) in Lao People's Demographic Republic (PDR) has not been examined since the national HBV vaccination program was started in 2002. Vaccine has been observed to be frozen at times during cold-chain transport in vaccination programs in Lao PDR and other developing countries, which will inactivate the vaccine. Therefore, this study used post-vaccination serologic testing to evaluate the effects of HBV immunization in Lao PDR.

methodsA cross-sectional serologic study was conducted among children (age range, 5-9 years) and mothers (15-45 years) who were randomly selected using probability-proportional-to-size sampling from central Lao PDR. Blood samples were collected as dried blood spots (DBS) and analyzed using chemiluminescent microparticle immunoassay to detect anti-hepatitis B surface (HBs) titers. We also evaluated the correlation between anti-HBs levels measured in DBS and serum among healthy healthcare workers in Vientiane.

resultsAnti-HBs titers from DBS were strongly correlated with serum levels (correlation coefficient = 0.999) in all 12 healthcare workers evaluated. A linear regression model showed that 10 mIU/mL of serum anti-HBs was equivalent to 3.45 mIU/mL (95% CI: 3.06-3.85) of DBS. Among 911 mother-child pairs tested, 171 children had documentation of vaccination. Of the 147 children who had received ≥3 doses of the hepatitis B vaccine, 1 (0.7%) was positive for anti-HBs. The remaining 24 children received the hepatitis B vaccine only twice, once or no dose.

conclusionsThe results showed extremely low positivity for anti-HBs among vaccinated children in central Lao PDR. Therefore, post-vaccination serologic testing is important to evaluate population immunity against HBV infection. DBS testing is a potential low-cost tool to evaluating the effectiveness of HBV vaccination programs.

Indexed as

AdolescentAdultChildChild, PreschoolCross-Sectional StudiesDried Blood Spot TestingFemaleHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B VaccinesHumansLaosLinear ModelsMaleMiddle AgedVaccinationHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B VaccinesChildrenCold chainDried blood spotHepatitis BPost-vaccination serologic testingVaccine

Identifiers

PMID31182043
PMCPMC6558699
OpenAlexW2953363507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.